Clinical Trial Update: PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating a PD-L1 antibody in combination with bevacizumab and hepatic arterial infusion chemotherapy for advanced hepatocellular c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• PD-L1 antibody

Snippet

Sponsor: West China Hospital | Conditions: Hepato Cellular Carcinoma (HCC) | Phase 2 | Status: RECRUITING